Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unicycive Therapeutics, Inc.

0.6490
-0.0149-2.24%
Post-market: 0.6410-0.0080-1.23%19:53 EDT
Volume:975.36K
Turnover:641.84K
Market Cap:67.36M
PE:-1.33
High:0.6880
Open:0.6639
Low:0.6300
Close:0.6639
Loading ...

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire
·
14 Oct 2024

Noble Financial Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)

TIPRANKS
·
13 Oct 2024

BRIEF-Octagon Capital Advisors Lp Reports 9.1% Passive Stake In Unicycive Therapeutics Inc As Of Sept 30

Reuters
·
12 Oct 2024

Octagon Capital Advisors Lp Reports 9.1% Passive Stake in Unicycive Therapeutics Inc as of Sept 30

THOMSON REUTERS
·
12 Oct 2024

Unicycive Therapeutics: A Buy Rating with a $2.50 Price Target Amid Clinical and Regulatory Advances

TIPRANKS
·
09 Oct 2024

Unicycive Therapeutics completes UNI-494 Phase 1 study

TIPRANKS
·
09 Oct 2024

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

GlobeNewswire
·
09 Oct 2024

BRIEF-Unicycive Therapeutics: Regained Compliance With Minimum Market Value Requirement - SEC Filing

Reuters
·
25 Sep 2024

Unicycive Therapeutics Inc Says on Sept 24, Received Notice From Nasdaq Co Regained Compliance With Minimum Market Value Requirement - SEC Filing

THOMSON REUTERS
·
25 Sep 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

GlobeNewswire
·
24 Sep 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

GlobeNewswire
·
20 Sep 2024

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

GlobeNewswire
·
17 Sep 2024

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

GlobeNewswire
·
16 Sep 2024